68 Upper Extremity Disability Assessment Following Breast Cancer Surgery Using QuickDASH in an Ethnic Minority Population

Publication
Article
Miami Breast Cancer Conference® Abstracts Supplement42nd Annual Miami Breast Cancer Conference® - Abstracts
Volume 39
Issue 4
Pages: 53-54

68 Upper Extremity Disability Assessment Following Breast Cancer Surgery Using QuickDASH in an Ethnic Minority Population

68 Upper Extremity Disability Assessment Following Breast Cancer Surgery Using QuickDASH in an Ethnic Minority Population

Background/Significance

Breast cancer surgery increases risk of upper extremity disability. The Quick Disabilities of the Arm, Shoulder, and Hand (QuickDASH; QD) tool is validated to assess upper extremity functionality in patients undergoing surgery for breast cancer. Despite evidence of poorer outcomes among Black breast cancer survivors, studies lack ethnic minorities and analysis of contributing factors. This study explores postoperative upper extremity disability in ethnic minority breast cancer patients at a single Bronx institution.

Materials and Methods

A retrospective review was conducted on surgical breast cancer patients (January 2022-July 2024) with pre- and postoperative QD assessments. Kruskal Wallis, Mann-Whitney, and Spearman’s Rank Correlation analyses were performed.

Results

Among 100 patients, the mean postoperative QD score was 8.9 (± 17.3), with a mean increase of 2.3 (± 15.0) over 161 (± 107) days. Preexisting shoulder pathology significantly increased postoperative QD scores (P = .045). While lymphedema (n = 11) was not significant (P = .25), adjuvant chemotherapy (P = .075) and higher body mass index (BMI; P = .082) showed potential associations. Neoadjuvant chemotherapy improved scores between pre- and postoperative (P = .039). Surgery type, axillary surgery, radiation, and previous surgeries were not significant.

Conclusion

Preexisting shoulder pathology increased postoperative QD scores, which may suggest a role for preoperative rehabilitation. Neoadjuvant chemotherapy improved outcomes. Adjuvant chemotherapy and higher BMI showed trends toward significance. Larger studies with greater power are needed to confirm these findings and tailor treatments to mitigate upper extremity disability.

Articles in this issue

68 Upper Extremity Disability Assessment Following Breast Cancer Surgery Using QuickDASH in an Ethnic Minority Population
68 Upper Extremity Disability Assessment Following Breast Cancer Surgery Using QuickDASH in an Ethnic Minority Population
70 Malignancy Upgrade Rates of Discordant Breast Lesions
70 Malignancy Upgrade Rates of Discordant Breast Lesions
71 Beyond the Surface: Suspicious Nipple Lesions
71 Beyond the Surface: Suspicious Nipple Lesions
72 Breast Cancer After Breast Augmentation: A Multicenter Collaborative Study Of Patient Management and Outcomes
72 Breast Cancer After Breast Augmentation: A Multicenter Collaborative Study Of Patient Management and Outcomes
73 Short- and Long-Term Outcomes in Use of Titanium-Coated Polypropylene Meshes in Immediate Breast Reconstruction: A Cost-Effective and Safe Option?
73 Short- and Long-Term Outcomes in Use of Titanium-Coated Polypropylene Meshes in Immediate Breast Reconstruction: A Cost-Effective and Safe Option?
74 Lessons Learned From a Breast Surgery ERAS Program in an Oncologic Ambulatory Center
74 Lessons Learned From a Breast Surgery ERAS Program in an Oncologic Ambulatory Center
75 Comparing 21-Gene Assay Recurrence Scores Before and After Preoperative Radiation Boost in Patients Enrolled in a Phase 2 Prospective Clinical Trial
75 Comparing 21-Gene Assay Recurrence Scores Before and After Preoperative Radiation Boost in Patients Enrolled in a Phase 2 Prospective Clinical Trial
76 Electromagnetic Chip Bracketed vs Wire Bracketed Localization in Breast Conserving Surgery
76 Electromagnetic Chip Bracketed vs Wire Bracketed Localization in Breast Conserving Surgery
77 A Radio Opaque Suture May Improve Radiation Target Delineation in Post Lumpectomy Patients With Breast Cancer: A Retrospective Analysis
77 A Radio Opaque Suture May Improve Radiation Target Delineation in Post Lumpectomy Patients With Breast Cancer: A Retrospective Analysis
78 Comparison of Positive Margin Rate of Breast Cancer in Higher BMI Patients
78 Comparison of Positive Margin Rate of Breast Cancer in Higher BMI Patients
79 Case Series of Pathologic Upgrade After Reconstructive Breast Surgery
79 Case Series of Pathologic Upgrade After Reconstructive Breast Surgery
81 Assessing Recurrence Likelihood in Hormone Receptor–Positive/HER2-Negative Breast Cancer Patients Directly From MRI Using Imaging AI
81 Assessing Recurrence Likelihood in Hormone Receptor–Positive/HER2-Negative Breast Cancer Patients Directly From MRI Using Imaging AI
82 Efficacy, Safety, and Biomarker Analysis of ICARUS-BREAST01: A Phase 2 Study of Patritumab Deruxtecan (HER3-DXd) in Patients With HR+/HER2– Advanced Breast Cancer
82 Efficacy, Safety, and Biomarker Analysis of ICARUS-BREAST01: A Phase 2 Study of Patritumab Deruxtecan (HER3-DXd) in Patients With HR+/HER2– Advanced Breast Cancer
TPS 83 ELAINE 3: Open-Label, Randomized, Multicenter, Phase 3 Study of the Efficacy and Safety of Lasofoxifene Plus Abemaciclib for Treating Locally Advanced or Metastatic, ER+/HER2–, Breast Cancer With an ESR1 Mutation
TPS 83 ELAINE 3: Open-Label, Randomized, Multicenter, Phase 3 Study of the Efficacy and Safety of Lasofoxifene Plus Abemaciclib for Treating Locally Advanced or Metastatic, ER+/HER2–, Breast Cancer With an ESR1 Mutation
84 EQUALS: Vaginal/Sexual Health in Patients With Estrogen Receptor–Positive/HER2- Metastatic Breast Cancer
84 EQUALS: Vaginal/Sexual Health in Patients With Estrogen Receptor–Positive/HER2- Metastatic Breast Cancer
Recent Videos
Prior studies, like the phase 3 VISION trial, may support the notion of combining radiopharmaceuticals with best supportive care.
Beta emitters like 177Lu-rosopatamab may offer built-in PSMA imaging during the treatment of patients with metastatic castration-resistant prostate cancer.
Ongoing ctDNA analysis may elucidate outcomes associated with divarasib plus migoprotafib for those with KRAS G12C–positive NSCLC.
Clinical trials conducted in recent years demonstrate the benefit of integrative oncology for patients undergoing treatment for cancer.
Multidisciplinary care can help ensure that treatment planning does not deviate from established guidelines for inflammatory breast cancer management.
Photographic and written documentation can help providers recognize inflammatory breast cancer symptoms across diverse populations.
The use of guideline-concordant care in breast cancer appears to be more common in White populations than Black populations.
Related Content